Mandate

Vinge advises Blue Wolf Capital Partners in connection with the acquisition of seven manufacturing and development facilities from Recipharm

Vinge has, together with Kirkland & Ellis, advised Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle market private equity firm specializing in the healthcare and industrial sectors, in connection with the acquisition of seven manufacturing and development facilities in Sweden, France, and Spain, from Recipharm Group, a contract development and manufacturing organization (“CDMO”) headquartered in Stockholm.

The seven facilities have been a part of Recipharm for over a decade and have focused on the manufacturing and development of oral solid, semi-solid and liquid dosage form pharmaceutical products. The facilities serve over 120 customers around the world and have a strong track record of quality and regulatory compliance. Together these sites are to form a new independent CDMO platform with continued focus on pharmaceutical manufacturing operating under a new corporate name to be announced after the transaction closes.

Vinge’s team consisted of among other Jonas BergströmMatthias Pannier, Carl Sander, Per Kling and Alexander Rüdén (M&A), Sam Seddigh, Emil Lindwall and Agnes Pigg (Employment), Johan Cederblad, Lina Österberg and Madelene Andersson (Real Estate and Environment) Stojan Arnerstål (Life Science and Regulatory), Mathilda Persson, Fredrika Hjelmberg, Christoffer Nordin, Carla Zachariasson and Elis Allmark (Commercial Contracts and Separation), Daniel WendelssonDavid Olander, Hilda Ivarsson and Hanna Lemne (FDI) and Anna Ekdahl Roos (Transaction Support).

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025